• Doximity recently released a report showing that 94% of U.S. physicians are either using or interested in adopting AI in clinical practice, highlighting growing integration across both clinical and administrative workflows.
• The study also found that while physicians see AI as a way to cut administrative burden and free up more time with patients, 71% remain concerned about its accuracy and reliability, underscoring a tension between enthusiasm and caution.
• We’ll now examine how this surge in physician AI interest, alongside lingering accuracy concerns, could influence Doximity’s broader investment narrative.

This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

Doximity Investment Narrative Recap

To own Doximity, you have to believe its physician network can keep deepening engagement and gradually monetize AI workflows, even as pharma ad spend remains the core revenue engine. The new AI report reinforces that doctors are actively experimenting with AI, but lingering concerns about accuracy mean the near term catalyst still hinges more on adoption and monetization of tools like Scribe than on sentiment alone, while reliance on pharma budgets remains the biggest immediate risk.

The most relevant recent announcement here is Doximity’s Q3 2025 results and FY 2026 guidance, which frame how much financial room the company has to keep investing in AI while offering many features for free. Revenue of US$185.05 million in Q3 and full year guidance of about US$642.5 million to US$643.5 million set expectations for growth, so any future shift from “free” to paid AI tiers could become a key catalyst relative to those numbers.

Yet beneath the AI enthusiasm, investors should also consider how Doximity’s dependence on pharma marketing and emerging AI competition could...

Doximity's narrative projects $805.8 million revenue and $280.5 million earnings by 2028. This requires 11.0% yearly revenue growth and about a $45 million earnings increase from $235.1 million today.

Uncover how Doximity's forecasts yield a $63.57 fair value, a 156% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could reach about US$812.6 million and earnings about US$399.3 million by 2028, but with this fresh AI adoption data and rising competitive risks around automation, you can see how opinions on Doximity’s upside might spread even further apart from here.

Explore 9 other fair value estimates on Doximity - why the stock might be worth just $25.00!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Doximity research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Doximity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Doximity's overall financial health at a glance.

Looking For Alternative Opportunities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.